Held in Rio de Janeiro, the 21st International Myeloma Society (IMS) Meeting and Exposition, in combination with the 8th Nursing and Allied Health Symposium brought together myeloma specialists from around the globe. The events spanned 25–28th September 2024 and Myeloma UK’s attendance ensured our contributions to myeloma patient care were shared on the international stage
DetailsWe are excited to announce that Myeloma UK will once again be attending the American Society of Hematology (ASH) Annual Meeting in 2024! As a cornerstone for haematology professionals worldwide, we are delighted to be part of it.
DetailsIn May, Myeloma UK showcased a new initiative to improve Support Groups for myeloma patients at Myeloma Patients Europe (MPE) Annual Masterclass. This new initiative, the Partnership Programme, has been co-produced with Support Group Leaders (SGLs) and is a way for SGLs to share best practice with one another.
DetailsIn September 2024, Lord Darzi published a review of the NHS in England. Here, our Senior Policy Officer Amy Capper shares her thoughts on the review, the response from the government and what it means for people affected by myeloma and their clinical teams.
DetailsThis latest update presents critical developments in myeloma treatment appraisals by NICE and the SMC.
Stay informed about the latest recommendations, appeal hearings, and upcoming assessments shaping the treatment options for patients and healthcare professionals.
DetailsSix more hospitals have gained the prestigious CSEP accreditation this quarter, highlighting their outstanding contributions to myeloma care and two more hospitals have achieved reaccreditation.
Explore some of the exceptional achievements and highlights that showcase these hospitals’ commitment to exceptional patient care.
In June, the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS) published a comprehensive good practice paper outlining recommendations for the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients. Here we discuss this major step towards realising suitable provision for this unmet patient need.
DetailsWe caught up with Myeloma Clinical Nurse Specialist (CNS) Sue Robb, and Consultant Haematologist and Myeloma UK Chief Clinical and Scientific Officer, Professor Graham Jackson, just before they headed off to the Myeloma UK London Paris Ride start line. In this Q&A, they tell us about their motivations for supporting Myeloma UK and how, collectively, we create change together.
DetailsOrder the free Myeloma UK Patient Diary for your patients today. Our Patient Diary has been designed to help people living with myeloma keep a record of appointments, test results and treatments.
DetailsThe British Society for Haematology (BSH) and the UK Myeloma Society have published a comprehensive Good Practice Paper on the diagnosis and initial treatment of transplant-eligible high-risk myeloma patients. Authored by leading experts in the field, this paper provides crucial recommendations based on the latest genetic diagnostics and prospective clinical trial evidence for high-risk myeloma.…
Details
